iifl-logo-icon 1

Sun Pharmaceuticals Industries Ltd Balance Sheet

1,887.55
(-0.50%)
Oct 22, 2024|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

239.93

239.93

239.93

239.93

Preference Capital

0

0

0

0

Reserves

23,454.47

23,508.43

24,348.02

26,698.54

Net Worth

23,694.4

23,748.36

24,587.95

26,938.47

Minority Interest

Debt

11,226.91

7,790.82

5,074.04

7,358.12

Deferred Tax Liability Net

832.04

950.45

1,065.43

631.95

Total Liabilities

35,753.35

32,489.63

30,727.42

34,928.54

Fixed Assets

8,502.85

9,564.58

10,541.42

10,759.17

Intangible Assets

Investments

12,429.97

12,613.24

15,548.87

15,537.2

Deferred Tax Asset Net

1,826.56

1,982.84

1,389.47

1,969.4

Networking Capital

12,655.58

7,907.69

2,712.7

6,301.79

Inventories

3,423.62

3,989.19

3,403.74

3,423.42

Inventory Days

79.71

88.51

Sundry Debtors

8,834.16

7,125.02

4,245.16

6,585.24

Debtor Days

99.41

170.27

Other Current Assets

6,541.28

6,241.79

6,167.29

5,731.33

Sundry Creditors

-2,653.49

-3,147.44

-3,037.85

-4,133.61

Creditor Days

71.14

106.88

Other Current Liabilities

-3,489.99

-6,300.87

-8,065.64

-5,304.59

Cash

338.39

421.28

534.96

360.98

Total Assets

35,753.35

32,489.63

30,727.42

34,928.54

Sun Pharma.Inds. : related Articles

Sun Pharma's Hair Loss Drug Approved by USFDA
26 Jul 2024|01:45 PM

The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.

Read More
Mayne Pharma Sues Sun Pharma in Patent Dispute
25 Jul 2024|11:57 AM

IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.

Read More
USFDA grills Sun Pharma for manufacturing issues at Dadra facility
4 Jul 2024|11:24 AM

The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp